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Humans are subjected to various diseases; hence, proper diagnosis helps avoid further disease
consequences. One such severe issue that could cause significant damage to the human liver is the
hepatitis C virus (HCV). Several techniques are available to detect HCV under various categories, such as
detection through antibodies, antigens, and RNA. Although immunoassays play a significant role in
discovering hepatitis viruses, there is a need for point-of-care tests (POCT). Some developing strategies
are required to ensure the appropriate selection of POCT for HCV detection, initiate appropriate antiviral
therapy, and define associated risks, which will be critical in achieving optimal outcomes. Though
molecular assays are precise, reproducible, sensitive, and specific, alternative strategies are required to
enhance HCV diagnosis among the infected population. Herein, we described and assessed the potential
of various microfluidic detection techniques and confirmatory approaches used in present communities.
In addition, current key market players in HCV chip-based diagnosis and the future perspectives on the
basis of which the diagnosis can be made easier are presented in the present review.Introduction
Hepatitis C virus
A virus is an infectious agent that incorporates into body cells
and is programmed to proliferate rapidly. The hepatitis C virus
(HCV) is a 50–60 nm long single-stranded RNA virus, as shown
in Fig. 1(a and b) that causes liver disease, followed by cell
damage. However, the virus itself does not cause the most
considerable damage to the liver. A signicant damage to the
liver is attributable to inammation, which develops through
the body's immune response to ght the virus. When the body
begins to ght the disease, it causes cell damage and ultimately
leads to brosis, where hard but non-functional brous tissues
replace the liver cells. The HCV infection may be symptomatic
or asymptomatic but both lead to chronic infection. In chronic
hepatitis C, the damage caused by inammation is sufficient to
harm the liver but unfortunately, it is not adequate to clear the
virus entirely. This means that inammation continues for
a long time, engendering ultimate tissue damage and less viral
clearance. Hepatitis C may eventually cause the cirrhosis of liver
or even hepatocellular carcinoma (HCC), if le unchecked.13
Fig. 1(c) depicts the progression of HCV infection. Patients with
chronic hepatitis C (CHC) are at high risk of life-threateningElektronik, Universiti Teknikal Malaysia
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63complications, including cirrhosis in 20% of the cases and
HCC at an incidence of 4%–5% per year in cirrhotic
patients.14–18 Epidemiological reports suggested that HCV is
related to several extrahepatic manifestations, including resis-
tance to insulin, type 2 diabetes mellitus, glomerulopathies,
and oral manifestations.19–22 However, most patients with HCV
infection could advance to chronic hepatitis but about 15%–
40% of them spontaneously clear the virus.27Statistics
Globally, 71 million people were estimated to have CHC infec-
tion (WHO). In 2016, there were approximately 399 000 notied
HCV global mortalities, mostly due to cirrhosis and HCC.
Estimates have shown that over the years, somewhere between
435 000 and 500 000 HCV cases have accumulated in Malaysia,
accounting for 2.5 percent of the general population (https://
www.mac.org.my/v3/the-hidden-epidemic-of-hepatitis-c/,
retrieved on March 2019). Acute HCV cases account for about
15%–20% of the total cases. Post-acute HCV infected patients
have 50–80% chances of developing chronic infections.
Approximately 170 million people across the world have been
infected with HCV.29 The Center for Disease Control and
Prevention (CDC) estimated that only 30%–50% of Americans
are aware of HCV infection. Despite 3.2 million of the living
population with CHCV infection, 50%–70% are unaware of their
health status.33 HCV infection is an increasing problem in
Malaysia, as more people are tested for HCV antibodies. In
Malaysia, approximately 453 700 people were infected with HCV
in 2009 (2.5 percent of the population age of 15–64); 59% of
them are infected by injecting drugs. However, there is littleThis journal is © The Royal Society of Chemistry 2021
Fig. 1 (a) Structure of HCV (this figure has been adapted from ref. 2 with permission from Healthline Media, copyright: 2017). (b) HCV genome,
polyprotein precursor, and initiation of the viral core assembly (this figure has been reproduced from ref. 7 with permission from Baishideng
Publishing Group, copyright: 2015). (c) HCV infection history (this figure has been adapted from ref. 12 with permission from Medknow,
copyright: 2014).


































View Article Onlineawareness of hepatitis C in Malaysia.3,34 In 2000, there were 550
cases of hepatitis C with an occurrence rate of 2.5/100 000
population; in 2004, there were 741 cases with an occurrence
rate of 2.9/100 000 population and in the year 2013, the occur-
rence rate grew to 6.77/100 000, which indicates the rising trend
of the disease, as shown in Fig. 2.3 Genotypes 3 and 1 are the
most common genotypes in Malaysia. Many studies have shown
that this genotype distribution in Malaysia has remained
unchanged in the last 15 years. The prevalence estimated for
females is signicantly lower than that for males and the esti-
mated number of HCV antibody-positive males in Malaysia is
much higher (84 percent) than for the other two ethnic groups.
Parenteral drug use (85 percent), blood transfusion (3 percent),
and dialysis were identied as the main modes of HCV trans-
mission.36,37 The other major modes of transmission of HCV are
via the reuse of medical equipment with inadequate steriliza-
tion, therapeutic injections, and blood-exposed sexual prac-
tices.12,39 In the United States, injected drug use is the most
common risk factor, accounting for >60% of HCV infections.
Unregulated and unlicensed tattoo centers applied by friends or
in prison increase HCV acquisition.41–43 Moreover, non-injecting
drug users who sniff or smoke heroin, cocaine, crack, or
methamphetamine using pipes that may cause burns in the oral
mucosa are susceptible to 2.3–35.3% risk of acquiring HCV.44 In
Malaysia, the National Strategic Plan for hepatitis B and C
(NSPHBC) was developed to eliminate hepatitis by 2030 through
prevention programs, diagnostic, treatment, and care
services.45–47 The detection of HCV infection at an earlier stage
provides several advantages, such early antiviral treatment for
the prevention of consequences of the disease and reduction in
the risk of infection transmission.48,49Microuidics
The commonly addressed disadvantage in the conventional
technique is that it requires high skill levels and lag portability.
The throughputs are low, even when the drawbacks areThis journal is © The Royal Society of Chemistry 2021removed. Trapping and isolation of single cells are the initial
steps involved in single-cell investigations. Hence, the intrica-
cies of cells and analytes could be overridden through micro-
uidics as they can process and analyze the sample (typically
between microliter to nanoliter) inside the device and furnish
high-throughput.50 A suitable and specic device dimension is
imposed with high precision to accurately manage the sample
within the microchannel. In general, the microuidic channel
dimensions are from 10 to 100 mm with promising application
in biological and chemical analysis in order to assure every need
of research with accurate results.51–54 The micro-level dimen-
sions of the ow channels used in the biochip equal the size of
the biological cell samples.
Microuidic devices currently play an imperative role in
numerous biological, chemical, and engineering applications,
where the necessary channel and feature dimensions are
fabricated through multiple methods.55–58 Commercial micro-
uidic devices are produced through photolithography, injec-
tion molding, and hot embossing.59 There is an obvious
attraction in the single-step fabrication of the entire micro-
uidic device. Henceforth, 3D printing techniques with rapid
realization of the model are potentially accepted.60 As a general
rule, choice of the fabrication method is determined by several
factors, such as the available technologies and equipment, cost,
speed, fabrication capabilities (e.g., desired feature size and
prole), and the preferred material substrate.
A variety of materials with properties such as transparency,
non-uorescence, and biocompatibility have been developed to
meet the need for microuidics.61 A wide range of materials
have been employed in the fabrication process, such as silicon,
glass, silicone-based elastomers, and PDMS. Hydrogels and
plastics are also used in the fabrication of devices for biological
assays and commercial implements. Paper, a fabric matrix
made of cellulose, is the most recently introduced material in
microuidic chip fabrication.62 Apart from the quality of the
results, the reduction in time, savings in space, reagents, and
minimum sample volumes involved (order of microliters) areAnal. Methods, 2021, 13, 740–763 | 741
Fig. 2 (a) Graphical illustration of HCV seroprevalence in Malaysia (this figure has been reproduced from ref. 3 with permission from Professional
Medical Publications, copyright: 2013). (b) Awareness created for different stages of anti-HCV detection procedures followed in China (this figure
has been adapted from ref. 8 with permission from Dove Medical Press, copyright: 2011). (c) Depicts the global distribution of HCV genotypes
among people (this figure has been reproduced from ref. 9 with permission from the National Center for Biotechnology Information, copyright
2018).


































View Article Onlinesome of the remarkable advantages of paper-based micro-
uidics.63,64 Due to the low fabrication cost, it makes the device
easily disposable and eliminates the cross-contamination of the
results.65,66 Microuidic devices developed to analyze the HCV
viral sample loads are antibody cell-based microuidic systems,
a whole-cell pathogen diagnostic approach for detecting hepa-
titis B virus (HBV), HCV, and human immunodeciency virus
(HIV). Moreover, the microuidic quantum dot (QD)-based
barcodes deliver the multiplex high-throughput detection of
HBV, HCV, and HIV.67 Thus, the microuidics domain plays
a vital role in the development of HCV diagnostic testing kits.Literature search performed
The literature search was performed using Google Scholar and
the investigation was carried out for the terms “hepatitis virus,
HCV detection, rapid diagnosis, point-of-care (POC) diagnosis742 | Anal. Methods, 2021, 13, 740–763of HCV, and HCV microuidic chips” for the period 2005–2019.
From the search, few relevant articles were handpicked and
explained accordingly in the year-wise order. In Fig. 3(a), the bar
graph illustrates the widespread publications on HCV detection
methods during 2005–2019. The survey outcomes witnessed
that more signicant research was concentrated on HCV anti-
body detection than other techniques. In contrast, paper-based
detection techniques are only 10% of all the detection methods;
hence, further investigations in this domain are essential. This
review article will be valuable for researchers who plan to
explore the eld of HCV diagnosis further.
Patent analysis and current key market players in the eld of
microuidic chips for the rapid diagnosis of hepatitis C
A patent analysis was performed in Google Patents search tool,
using the keyword hepatitis C virus detection or diagnosis
chips, and the key market players are Institute of Basic MedicalThis journal is © The Royal Society of Chemistry 2021
Fig. 3 (a) Percentage of 40 940 publications in HCV detection during 2005–2019; (b) patent analysis on hepatitis C virus diagnostic chips.


































View Article OnlineSciences, Chinese Academy of Military Medical Sciences (CN),
Shanghai Bohua Gene Chip Technology Co., Ltd. (CN), BioCore
Co., Ltd. (US), Fuz Taipu Biological Science CO., Ltd. (CN),
Fujirebio (US), Shanghai Fosun Medical Technology Develop-
ment Co., Ltd. (CN), Shanghai Bohua Gene Chip Technology
Co., Ltd. (CN), Bioseum Co., Ltd. (CN), Institut Pasteur (US),
Third Wave Technologies, Inc. (US), Eos Biotechnology, Inc.
(WO), Fio Corporation (CA,US), ITI Scotland Ltd (CA), Biopico
Systems Inc (US), Geneasys Pty Ltd (US), Samsung Electronics
Co Ltd (US), Talis Biomedical Corporation (EP), Triad National
Security, Llc (US), Nanobiosym, Inc. (US), Credo Biomedical Pte.
Ltd (TW), President and Fellows of Harvard College (US), Sur-
netics, Llc (WO), National Institute of Infectious Diseases (JP),
Biological Engineering Co., Ltd. (CN), Abbott Laboratories (JP),
Gene Co., Ltd. (CN), Shandong Boke Biological Industry Co.,
Ltd. (CN), Institute of Chemistry, Chinese Academy of Sciences
(CN), Hunan Shengxiang Biotechnology Co., Ltd. (CN), and
Shimadzu Research Laboratory Co. Ltd. (CN). The patent anal-
ysis of key market players in HCV is shown in Fig. 3(b).Detection and diagnostic approaches
To diagnose and treat infected persons is the primary intention
of viral infection diagnosis. It engenders the prevention of the
headway of disease and the virus spread. The onset of HCV
infection does not possess any specic indicators since most
primary patients are asymptomatic. HCV viremia nds its
existence besides the normal level of serum alanine amino-
transferase (ALT).68 Henceforth, various virological methods are
practiced to diagnose HCV infection.69 This article enlightened
readers about the detection based on techniques and
biomarkers, and has categorized them for better
understanding.
Direct and indirect testing methods are the most commonly
employed virological approaches to assess viral infections.
Fig. 4 depicts the overview of various assays practiced for the
diagnosis of HCV infection, which includes microuidics-based
and non-microuidics-based assays available in recentThis journal is © The Royal Society of Chemistry 2021times.12,70–75 Indirect detection tests consist of viral-induced
antibodies, which include IgM to diagnose recent infections
and IgG for current or previous infections. Anti-HCV IgMs are
found in 50%–93% of acute hepatitis C patients along with
50%–70% of CHC patients.76 Hence, in clinical practice, IgM
assays are not employed since anti-HCV IgM does not act as
a suitable marker of acute HCV infection.77,78 The protein chip
assay (PCA), chemiluminescent microparticle immunoassay
(CMIA), enzyme-linked immunosorbent assay (ELISA), lateral
ow immunoassay (LFIA), electrochemical immune sensor
array, and rapid immune chromatographic assay are some of
the assays adapted in antibody detection. The virus isolation,
viral antigen detection, and viral nucleic acid detection are the
detection parameters of direct tests. The isolation and culture of
HCV using clinical specimens is a challenging task at present.
However, it can be isolated via a traditional single strain isola-
tion methodology. In microuidics, cost-effective and straight-
forward single-cell trapping and isolation are available.79 But
currently, it is difficult to isolate and culture HCV using clinical
specimens. Hence, HCV viral isolation is in demand for detec-
tion, analysis, and research. In RNA detection, magnetic beads,
loop-mediated isothermal amplication (LAMP), transcription-
mediated amplication (TMA), and reverse transcription-
polymerase chain reaction (RT-PCR) are available. Similarly,
magnetic microparticle assay, PCR, atomic force microscopy
(AFM), and nucleic acid amplication test (NAAT) are adapted
in core-Ag detection.Techniques used for HCV detection
Several techniques are available based on the methods, mate-
rials, and equipment used. In this section, the HCV detection
techniques based on amplication, rapid immunoassay system,
and sensors are enlisted, as shown in Fig. 5. In amplication,
non-isothermal amplication and isothermal amplication are
available.80–83 The immunoassay system comprises of lateral
ow assays and immuno-ltration assays. Moreover, electro-
chemical and optical sensors are available for HCV detection.Anal. Methods, 2021, 13, 740–763 | 743
Fig. 4 Overview of various HCV diagnostic assays practiced in recent times.


































View Article OnlineThe illustrations and process of various HCV detection tech-
niques based on microuidics are shown in Fig. 6.Non-isothermal amplication
 Reverse Transcription Polymerase Chain Reaction (RT-PCR) is
used to convert RNA viral genomes to complementary DNA
(cDNA) templates in order to detect RNA expression and clone
expressed genes.84,85 The development of “Digital” single-
molecule measurements is attractive for the quantitative
measurement of RNA concentration, with typically limited
dynamic range. Hence, Shen et al. designed and tested two
microuidic rotational slip chip platforms for the quantitative
analysis of HCV RNA through multivolume digital RT-PCR with
an extensive dynamic range by adding additional wells.6
 Real-time PCR is used for the qualitative and quantitative
investigation of viral nucleic acids for therapy monitoring.86 The
SYBR Green RT-PCR assay reported by Vázquez-Morón et al.
showed that the limit of detection (LOD) of HCV is 5000 copies
per mL in dried blood spot (DBS) specimens with 100% effi-
ciency. However, it is not an effective screening of HCV due to
its very high detection limit (DL).61 In the eld of bedside clin-
ical tests, RT-PCR is not suitable for POCT due to the require-
ment of a laboratory environment and equipment with trained
professionals. Hence, isothermal amplication is brought into
existence for addressing these issues.Isothermal amplication
 Transcription Mediated Amplication (TMA) uses two
enzymes, such as RNA polymerase and reverse transcriptase, for
rapid RNA/DNA amplication.87 TMA-based assays are highly744 | Anal. Methods, 2021, 13, 740–763sensitive due to their lower DL and can detect the non-
detectable HCV RNA by PCR methods to avoid the recurrence
of infection.88
 Reverse Transcription Loop-Mediated Isothermal Ampli-
cation (RT-LAMP) in which LAMP amplies the DNA with high
specicity, efficiency, and rapidity under isothermal conditions,
which is combined with the reverse transcription step, is used
to detect RNA. Generally, the LAMP reaction necessitates four
primers to recognize six different regions of the target DNA.74
 Forward inner primer (FIP) comprises of F2 and F1c
regions at the 30-end and 50-end, respectively.
 Forward outer primer (F3 Primer) contains the F3 region
matching the F3c region of the template DNA.
 Backward inner primer (BIP) contains a B2 and B1c region
at the 30-end and 50-end, respectively.
 Backward outer primer (B3 Primer) contains a B3 region
complementary to the B3c region of the template.
Chang et al. presented a LAMP-based lab-on-disk optical
system that allows the simultaneous detection of viruses
through turbidity measurements.89 It has a wide range of
applications in POCT and rapid testing in food and environ-
mental samples.22
 Rolling Circle Amplication (RCA) is an isothermal enzy-
matic amplication method where short DNA or RNA primers
are amplied to form a long single-stranded DNA or RNA using
a circular DNA template and specic DNA or RNA poly-
merases.88 Liu et al. observed paper-based RCA with higher
efficiency than solution-based RCA. The amplied HCV DNA is
detected by conjugating with AuNP for colorimetric visualiza-
tion.90 The characteristic feature of amplication techniques for
HCV are enlisted in Table 1.This journal is © The Royal Society of Chemistry 2021
Fig. 5 Various microfluidics-based techniques adapted for HCV detection.


































View Article OnlineRapid immunoassay systems
 Lateral Flow Assays (LFA), commonly known as immuno-
chromatographic assays (ICA), are highly adapted for the qual-
itative analysis of nucleic acids and quantitative analysis of
protein for POCT. LFA consist of a sample pad, a membrane on
which the antigens/antibodies are immobilized, and an
absorption pad over a membrane strip assembled on a plastic
backing.88 The sample containing HCV IgG antibodies binds to
protein-A on colloidal gold, which binds to antigens coated on
the membrane, thus inducing a color change for detection.91 In
addition to that, Ryu et al. integrated a portable uorescence
reader (AFIAS-6 reader) to improve the sensitivity and to carry
out multiple simultaneous tests.1
 Immuno-Filtration Assay (IFA) is also known as ow-
through assay, where specic antigens are immobilized on
a porous immuno-ltration membrane for the subsequent
ltration and binding of HCV antibodies. The capturedThis journal is © The Royal Society of Chemistry 2021antibodies are then combined with antibody-specic IgG to
produce distinct colors on the region.92 Traditional IFAs are
commonly qualitative or semi-quantitative and are very
restricted for clinical diagnosis. Hence, Zhang et al. developed
an IFA, based on QDs, capped with both polyethylene glycol
(PEG) and glutathione as the uorescent labels for the quanti-
tative detection of C-reactive proteins, which is a well-known
diagnostic marker for acute viral and bacterial infections.93Sensors
 Electrochemical detection is the process of measuring the
electrical potential of the sample with the change in the virus
concentration.59 Thereby, Zribi et al. integrated electrochemical
sensors based on carbon nanotubes with ferrocene as a redox
marker for viral pathogenic DNA detection.94 Later, Aronoff-
Spencer et al. genetically engineered the yeast cell lines to
display HCV core Ag concatenated to the gold binding peptide,Anal. Methods, 2021, 13, 740–763 | 745
Fig. 6 Illustrations and process of HCV detection techniques. (i) Multivolume Digital RT-PCR (this figure has been adapted from ref. 6 with
permission fromACS, copyright: 2011). (ii) Illustrates the process of PCR (this figure has been reproduced from ref. 10 with permission from Taylor
& Francis, copyright: 2008). (iii) Portrays the process of TMA (this figure has been adapted from ref. 23 with permission from Oxford University
Press, copyright: 2008). (iv) Demonstrates the process of LAMP (this figure has been reproduced from ref. 24 with permission from Wiley-
Blackwell, copyright: 2018). (v) Illustration of the PEGylated QDs-based immuno-filtration assay (this figure has been reproduced from ref. 25
with permission from Dove Medical Press, copyright: 2015). (vi) Principle of RCA and the AFM image of the RCA product (this figure has been
adapted from ref. 28 with permission from Springer, copyright: 2016). (vii) Illustration of LFA. (viii) Illustration of anti-HCV core antibody detection
by fluorescence and electrochemical methods with a smartphone-based potentiostat (this figure has been adapted from ref. 30 with permission
from Else, copyright: 2016).
746 | Anal. Methods, 2021, 13, 740–763 This journal is © The Royal Society of Chemistry 2021










































primers Amplication Time Disadvantage Ref.
PCR DNA 95, 60, 72 2 30 cycles yield 109-fold
amplication
2–4 h  Required thermal cycler 95
 High time consumption
Minute contamination leads to
misleading results
TMA RNA and DNA 37 2 106-fold amplication Within 1–
2 h
 Requires pre-heating 10 and
96 Requires 3 enzymes
 Lower temperature increases
the non-specic interactions of
the primers
LAMP DNA 65 4–6 109-fold amplication Less than
1 h
 Complicated multiple primer
designs
97




RCA Circular DNA or
RNA
37 1 9000 nucleotides from a 34
nucleotides template




 Only a few DNA aptamers and
DNA enzymes have been used
 Variability of binding sites for
nano species immobilization is
rather limited


































View Article Onlineenabling single-step purication, surface preparation, and
deposition for optical imaging to electrochemical sensing.30
 Optical detection was carried out by Timurdogan et al.
using a 5 mW laser diode, a photodetector, lenses, and
embedded diffraction gratings at the tip of each cantilever. The
entire read-out electronics can be miniaturized and made
portable.4Detection based on biomarkers
Diagnosis and HCV management are crucial to enable diag-
nosis, treatment monitoring, and treatment selection in
reducing disease progression. Due to the advancement of easier
and earlier detection in protein chip assay (PCA), Chen et al.
developed a surface-enhanced laser desorption/ionization time-
of-ight mass spectrometric (SELDI-TOF-MS) method for the
detection of serum biomarkers in liver disease.100 Later,
Mukherjee et al. explained the serological assays, rapid diag-
nostic tests (RDTs), OraQuick HCV rapid antibody test, clinical
chemistry assays, molecular assays, and HCV genotyping
assays.40 On the other hand, Kamili et al. concentrated on the
challenges in HCV detection, the upcoming technologies to
distinguish acute and chronic HCV during their assay, and
concluded the importance of immunoassays for HCV core
antigen (HCV cAg) detection to reduce the cost and labor-
intensive NAT.101 Then, Foudeh et al. presented the status of
microuidic devices for pathogen diagnosis and emphasized
the innovative designs, strategies, and trends to throw light
upon the design and modication of various components to
develop lab-on-chip (LOC) devices.102 Moreover, Khuroo et al.
assessed the diagnostic accuracy and applicability of POCTs forThis journal is © The Royal Society of Chemistry 2021HCV, which stood as one of the critical analysis for the further
implementation of devices in POC diagnostics.103
One of the notable works of Li et al. was the study of the
general properties of HCV RNA and their protein composition
along with the screening methods and diagnostic tools, which
help in concluding the requirement of the new prophylactic
vaccine.27 Later, Trucchi et al. summarized three major unre-
solved issues: (i) the perspectives for the universal screening of
HCV, (ii) the need for direct-acting antiviral (DAA) resistance
testing in the future, and (iii) necessary preventive HCV
vaccine.104 Further, Chevaliez et al. reported the list of alterna-
tives to the standardized tests for the virological examination of
hepatitis B and C in POC testing, DBS, alternatives to nucleic
acid testing (NAT), and Food and Drug Administration (FDA)
approved RDTs.105 Later, Mane et al. proposed multiple detec-
tion techniques of HCV antibodies by considering ve different
RDTs, namely, Alere Truline, SD Bioline, Flaviscreen, advanced
RDTs, and OraQuick, where Alere Truline, Bioline, and Ora-
Quick had high specicity and sensitivity compared to other
techniques.106
Marwaha et al. focused on the currently increasing trends
and status of various generation tests involved in screening
HCV-infected blood donors from different countries. They also
discussed the sensitivity of the antibody, antigen, and combi-
nation assays. Furthermore, they recapitulated the importance
of combined antigen and antibody assays for HCV screening
and concluded that “fourth generation” combined antigen–
antibody assays will be the best approach for HCV screening in
resource-constrained environments.107 In recent times, oral
POCT was available for self-testing with comparable perfor-
mance to blood-based tests. This improves treatment initiationAnal. Methods, 2021, 13, 740–763 | 747


































View Article Onlineand patient care. Tucker et al. explained the importance of
POCT in sexually transmitted infections.108 Duchesne et al.
summarized the main challenges, advances to overcome the
difficulties in the eld of viral hepatitis, and the LOD for each
method.109 From these review articles, we are acquainted with
a plethora of detection techniques available for the detection of
HCV infection, each with a denite DL. We categorized all the
probable methods based on the detection modalities, i.e., the
detection of HCV RNA, antibodies, core antigen, and antigen
and antibody together beyond confronting the intricacies.
HCV RNA. Within the exposure of 2–14 days to HCV, HCV
RNA will appear in the bloodstream, which increases the
alanine aminotransferase (ALT) enzyme of the liver.110 Hsieh
et al. demonstrated a fast DNA sample and mutant detection in
the homogeneous liquid phase of the microdroplets through
molecular beacon (MB) as a DNA sensing probe. Furthermore,
they evaluated dynamic MB-DNA duplex formation using label-
free DNA.111 Later, Roh et al. proposed a QDs-supported RNA
oligonucleotide technique to detect HCV viral protein using
biochip through the immobilization of HCV non-structural
protein 5B (NS5B) on a glass chip.112 In addition, Roh et al.
developed a protein glass chip to visualize the QDs-based HCV
NS3 biomarker through a uorescent imaging probe using the
RNA aptamer coupled with QDs605.112 For the simultaneous
detection of multiple bio-molecules, Sochol et al. constructed
a microuidic chip that integrates both the microuidic mixing
of the mobile microbeads and hydrodynamic microbeads
arraying, and detected through ssDNAmolecular beacon probes
immobilized on polystyrene microbeads for uorescence visu-
alization and signal detection. For evaluation purposes, perfect
match (PM), one mismatch (SNP), and mismatch (MM) DNA
oligonucleotide sequence corresponding to perfect comple-
mentary for MB, a single base-pair mismatch to MB, and with
multiple base-pair mismatches to MB, respectively, were
used.113 Subsequently, Ember et al. fabricated DNA and protein
microarrays, which were directed against universal HCV deter-
minants for the rapid detection of HCV infection in clinical
samples that were more sensitive compared to the commercial
ones.114
The detection of HCV genotype was necessary for antiviral
therapy. PCR step, exonuclease digestion, and genotype detec-
tion steps were essential to predict the genotype, which could be
done in GenMark eSensor. Then, Sam et al. validated the LOD,
specicity, accuracy, and precision of the GenMark eSensor®.87
Mukaide et al. described the detection of mutations of the HCV
core protein gene in codon 70 through next-generation droplet
digital polymerase chain reaction (ddPCR) assay. This assay
possesses highly sensitive quantitative detection of single
nucleotide polymorphisms within the viral genomes and accu-
rately quantitates the total amount of HCV RNA.115 Later, Taq-
Man Array Cards (TAC) were developed for the rapid and
simultaneous detection of ve hepatitis viruses. The micro-
uidic technology allows sample distribution to individual RT-
PCR reactions and thereby, the TAC assay was done through the
ViiA7 instrument.116 Similarly, Chang et al. presented a LAMP-
based lab-on-disk optical system that allows the simultaneous
detection of HBV, HCV, and cytomegalovirus by measuring the748 | Anal. Methods, 2021, 13, 740–763turbidity of DNA samples. It consists of a disposable micro-
uidic disk, a temperature control system, a servo motor,
a control unit, and an SPR detection system.89
Lu et al. developed a powerful homogeneous electronic
monitoring platform to eliminate the intricacies of multiple
separation and rinsing steps and identify low concentration
nucleic acid through a negatively charged screen-printed
carbon electrode.117 When the high ow of uid passed to the
sensor of carbon nanotubes associated with ferrocene as the
redox marker, a very thin depletion layer was formed on the
surface, engendering a capture rate up to one DNA strand per
second.94 Portable microdevices for HCV-RNA purication and
detection lagged in early-stage detection. Thus, Vaghi et al.
developed a microdevice whose surfaces were treated to bear
optimal positive charges in order to purify HCV RNA from the
plasma by adsorbing HCV RNA and reverse-transcribed it into
cDNA for detection.118 To make it cheaper and more straight-
forward, Liu et al. successfully developed a fully functional
paper device for the detection of DNA or microRNA via target-
induced rolling circle amplication by capturing colorimetric
signals.90 Fig. 7 shows the different chips used in the detection
of HCV RNA.
Digital nucleic acid detection (dNAD) platform was devel-
oped by Chen et al. through the combination of emulsion
microreactors, single-molecule magnetic capture, and on-bead
LAMP for the detection of HCV DNA. Furthermore, the use of
a LAMP emulsier instead of PCR forgoes the thermocycler and
improves the amplication. Magnetic capture partitioned each
DNA with single encapsulated beads, thus enhancing the
sensitivity.119 Thereby, Llibre et al. designed an instrument that
focused on developing a POC assay for the qualitative detection
of HCV RNA through the PCR Genedrive instrument. The
Genedrive HCV assay has been evaluated through a case–
control study, which results in high sensitivity and specicity
for decentralized HCV nucleic acid amplication testing
(NAAT).120 Tu et al. provided a digital strategy for HCV RNA
detection using glucose-loaded liposomes as the labeling probe.
The detached glucose-loaded liposome was dissolved with
Triton X-100 aer the magnetic separation of the bead to release
the glucose molecules, which were detected by a digital gluc-
ometer.121 The sensitivity, DL, and disadvantages of each HCV
RNA detection technique in microuidics are summarized in
Table 2.
HCV antibodies. Detection of antibodies is considered to be
the simplest when compared to RNA and antigen detection.
Hence, more assays with different procedures are clinically
available. However, the HCV antibody develops aer 30–60 days
of exposure to HCV.110 Hence, within 6–12 weeks of infection,
the HCV antibodies are usually detectable.123 Daniel et al.
developed a fourth-generation ow-through immunoassay to
detect HCV-Ab and compared the outcome with the enzyme
immunoassay (EIA) and microparticle enzyme immunoassay
(MEIA). The NS3, NS4, and NS5 antigens of HCV were immo-
bilized on a porous immunoltration membrane, consisting of
three test dots, T1, T2, and a quality control or serum control
dot. When the serum/plasma sample is loaded on the
membrane, HCV-Ab binds to the immobilized antigen. UponThis journal is © The Royal Society of Chemistry 2021
Fig. 7 Various devices used for HCV RNA detection. (i) Microfluidic testing using compact disk microfluidic channels (this figure has been
reproduced from ref. 89 with permission from Hindawi, copyright: 2015). (ii) A dynamic bead-based microarray for parallel DNA detection (this
figure has been reproduced from ref. 113 with permission from IOP, copyright: 2011). (iii) Image of 96 microzones paper plate (this figure has
been reproduced from ref. 90 with permission from Wiley, copyright: 2016). (iv) SlipChip for multiplexed, multivolume digital RT-PCR with high
dynamic range (this figure has been adapted from ref. 6 with permission from ACS, copyright: 2011). (v) Protein biochip for viral protein detection
(this figure has been adapted from ref. 112 with permission fromWiley, copyright: 2010). (vi) On-chip genetic analysis of HCV (this figure has been
adapted from ref. 94 with permission from AIP, copyright: 2016). (vii) Hybridization and electrochemical detection mechanism (this figure has
been reproduced from ref. 87 with permission from Elsevier, copyright: 2013).


































View Article Onlinethe addition of protein A conjugate, the Fc portion of HCV-
specic immunoglobulin G binds, which results in a pinkish-
purple dot in the test region.124 The preparation, quality
control, and clinical evaluation of a protein chip were investi-
gated by Zhang et al. for the simultaneous detection of differentThis journal is © The Royal Society of Chemistry 2021HCV antibodies by six antigens arrayed onto the aldehyde-
coated slides and scanned using the Scanarray 3000
scanner.125 Later, Duan et al. described the rapid and simulta-
neous detection of HBV and HCV antibodies through PCA using
Nano-gold Immunological Amplication and Silver StainingAnal. Methods, 2021, 13, 740–763 | 749
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View Article Online(NIASS) method. The enhancing solution in the assay contains
silver ions and a reducing agent, which is buffered to an acidic
pH. Intense dark signals were obtained during immunogold
silver staining enhancement, where the colloidal nano-gold acts750 | Anal. Methods, 2021, 13, 740–763as a nucleation site for metallic silver deposition, thus making it
visible to naked eyes.126
Similarly, Xu et al. described a simple, rapid, and sensitive
protein microarray to determine two viral antigens and sevenThis journal is © The Royal Society of Chemistry 2021


































View Article Onlineviral antibodies of human hepatitis viruses in human sera. The
result was amplied using a tyramide signal amplication
system and assessed directly by the naked eye or analyzed
through a quantitative detector.127 To perform consecutive ow
(CF), Corstjens et al. developed and constructed a semi-
automatic microuidic module prototype that ts into the
existing UPlink-compatible cassettes. The CF format was
initially designed to detect human antibodies against HIV-1 and
2. However, for the multiplexed detection of various antibodies
from a single specimen, different test lines were placed trans-
versely across the linear ow (LF) strip without disturbing the
up-converting phosphor technology (UPT) reporter.31 Likewise,
Desbois et al. developed a visual, qualitative, and rapid assay to
detect anti-HCV IgG antibodies based on an immuno-
chromatographic test, where the membrane was stripped with
recombinant HCV antigens representing the core, NS3, NS4,
NS5 proteins, and a reagent control. IgG antibodies in the
sample were bound to protein-A on colloidal gold, followed by
the binding of antigens coated on the membrane, which
implied color change in the specic region of the membrane.91
Lee et al. compared the new, rapid, non-instrumented POC
test of OraQuick® HCV assay for ve specimen types with FDA-
approved laboratory methods and concluded that the rapid
anti-HCV test was a suitable aid in HCV Ab diagnosis.128
OraQuick® HCV Rapid Antibody Test utilizes an indirect
immunoassay method in a lateral ow device. It was a non-
invasive procedure while using oral samples. They used
a nitrocellulose strip where HCV antigens were immobilized on
a single test line. The antibodies bind to give a reddish-purple
line using colloidal gold, labeled with protein-A. However, the
sensitivity of the oral uid is slightly lower than the nger-stick
blood (FSB) specimens.129 In addition to that, Jewett et al.
evaluated the sensitivity and specicity with the other two pre-
market rapid POC tests.130 Similarly, Smith et al. evaluated the
sensitivity and specicity of the POC tests that utilize FSB and
two oral uid rapid assays from 3 manufactures. Finally, FDA
approved the OraSure assay for venous and FSB samples.131
Some of the FDA-approved antibody assays are Abbott HCV EIA
2.0, Advia Centaur™ HCV Assay, Architect Anti-HCV, AxSYM™
Anti-HCV, Elecsys™ Anti-HCV II, OraQuick™ HCV Rapid
Antibody Test, Ortho HCV Version 3.0 ELISA Test System, and
Vitros Anti-HCV.132 Some of the devices used in HCV antibody
detection are shown in Fig. 8.
Due to the prolongation of HCV, HCC may occur; thus,
Akada et al. immobilized the cysteine-tagged recombinant
antigenic proteins on maleimide-coated diamond-like carbon
(DLC) silicon chips to detect multiple auto-antibodies in HCC
individuals.5 To address the performance gap of high duration
conrmatory diagnosis, heterogeneous barcode immunoassay
was applied to capture HCV antibodies in the serum via the
electrophoreses of barcode-patterned gel.11 Mu et al. developed
a multiplexed microuidic paper-based immunoassay to
address the diagnostic challenges of HCV infection by inte-
grating the segmented assays rapidly and economically so as to
transform the diagnostic pathway for confronting HCV.35 The
main aim of Cha et al. was to give a piece of knowledge about
the clinical sensitivity and specicity of the OraQuick HCVThis journal is © The Royal Society of Chemistry 2021Rapid Antibody Test, which utilizes lateral ow immunoassay
that helps in comparing the performance of the biological
samples.133 Similarly, Scalioni et al. analyzed the performance of
the three rapid tests such as (1) WAMA Immuno-Rápido HCV,
(2) Bioeasy HCV Rapid Test, and (3) OraQuick HCV Rapid Test
from the samples that were obtained from different individuals
with different endemicity and progress risk factors. In all these
tests, recombinant antigens from the core and non-structural
regions of the HCV genome were immobilized on a test strip
for detection.134
Due to the requirement of telediagnosis in resource-limited
settings, Zhao et al. integrated the paper-based diagnostic
platform with multiplexing and telemedicine capabilities. This
can be achieved by detecting the HCV core antibodies in an
electrochemical immunosensor array and the output was read-
out through a handheld potentiostat integrated with a Blue-
tooth module.135 Similarly, an electrochemical microuidic
paper-based immunosensor array (E-mPIA) was integrated with
a handheld potentiostat for the diagnosis of the HIV/HCV co-
infection and remote transmission of the diagnostic results to
a host computer or smartphone for telemedicine.38 Parween
et al. reported human IgE, the antibody of hepatitis C virus core
antigen, and three 20 mer-oligonucleotides were detected by an
activated ultra-miniaturized assay plate (AUAP), where the
biomolecules were immobilized through covalent binding and
were quantied digitally.32 Robin et al. conducted a hospital-
based cross-sectional study on the serum samples to detect
HIV-1 and HIV-2, and the HCV antibodies in a manually oper-
ated, visually interpreted, lateral ow immunochromatographic
assay within 15 min irrespective of age and sex. According to the
results obtained, the HCV-seropositive sera were positive for
HCV RNA, whereas negative results were resolved of infection.
The authors also predicted that the triplex detection device has
shown very high sensitivity, specicity, as well as excellent
concordance with Chemiluminescent Microparticle Immuno-
assay (CMIA) Abbott results.136
For the qualitative detection of the HCV antibody, Ryu et al.
developed a uorescent LFIA (Lateral Flow Immunoassay)
employing Automated Fluorescent Immunoassay System
(AFIAS) through the optical signaling probe with a high signal-
to-noise ratio, an Eu(III) uorescent dye to improve the sensi-
tivity, and an automated uorescent strip reader to record the
uorescence intensity.1 Finally, for rapid POC test, Kweon et al.
developed EuDx-HE (A, B, C), a manually-operated and visually-
interpreted kit based on the immunochromatographic assay
with lateral ow consisting of a sample pad, a conjugate pad,
and a nitrocellulose membrane immobilized with HCV anti-
gens, to capture the antibodies. The architect immunoassay
analyzer evaluates the diagnostic accuracy of the kit.26 Though
the HCV antibody detection stepped into the new era of
surveillance, it additionally requires epidemiological mapping,
testing, and prevention.137 The sensitivity, DL, and disadvan-
tages of each HCV antibody detection technique in micro-
uidics are explained in Table 3.
HCV core antigen. During acute HCV infection, HCV cAg
develops before antibody production.138 Hence, the HCV core
antigen assay detects the HCV infection between 40 and 50 daysAnal. Methods, 2021, 13, 740–763 | 751
Fig. 8 Various devices used for HCV antibody detection. (i) Design of Automated Fluorescent Immunoassay System (AFIAS) (this figure has
been adapted from ref. 1 with permission from Korean Society for Laboratory Medicine, copyright: 2018). (ii) Auto-antibody detection on
protein array chips (this figure has been reproduced from ref. 5 with permission from Biomed Central, copyright: 2013). (iii) Schematic of
the microfluidic barcode assay and the antibody sandwich assay (this figure has been adapted from ref. 11 with permission from Royal
Society of Chemistry, copyright: 2013). (iv) Schematic of EuDx-HE (A, B, C) kit (this figure has been reproduced from ref. 26 with permission
from Wiley-Blackwell, copyright: 2019). (v) CF semi-automatic microfluidic device (this figure has been adapted from ref. 31 with
permission from Wiley-Blackwell, copyright: 2007). (vi) Illustration of the ultra-miniaturized assay technique on an ultra-miniaturized
assay plate (this figure has been reproduced from ref. 32 with permission from Springer, copyright: 2016). (vii) Images of craft punch
patterning with different designs; (viii) Paper-based immunoassay for ELISA and RIBA (figures (vii) and (viii) have been adapted from ref. 35
with permission from ACS Publications, copyright: 2014). (ix) Paper-based immunosensor array introduced in a handheld potentiostat (this
figure has been adapted from ref. 38 with permission from AAAS, copyright: 2012). (x) OraQuick HCV Test kit (this figure has been
reproduced from ref. 40 with permission from EVISA, copyright: 2015).


































View Article Onlineearlier than the current third-generation HCV antibody
screening assays.139 Bouzgarrou et al. described the HCV core
antigen testing by Ortho trak-C assay (OTCA) in dialysis patients
in developing countries where RT-PCR techniques remain
unavailable. It consists of a microplate coated with antibodies752 | Anal. Methods, 2021, 13, 740–763that bind the HCV antigens upon the addition of conjugate (Fab
fragments of the horseradish peroxidase). The addition of O-
phenylenediamine (OPD) oxidizes the conjugate and yields
a reddish product.138 Although the current HCV antigen assay
techniques are not as sensitive as NAT, however, they areThis journal is © The Royal Society of Chemistry 2021
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View Article Onlinea signicant improvement than the HCV antibody assay as it
detects within the window period.140 Hence, Lee et al. paved the
rst step toward developing high affinity and specicity RNA
aptamer to bind the HCV core antigen for HCV diagnosis by
applying the core antigen-specic aptamers to sol–gel-based
chips.141 Timurdogan et al. developed a label-free and real-
time analyte monitoring and optical biomolecule detection
using a 5 mW laser diode through resonant microcantilever
arrays as shown in Fig. 9.4
Ivanov et al. incubated the serum samples through reversible
biospecic-shing and mass spectrometry (MS). They then
visualized the immune complexes on the surface of the atomic
force microscopy (AFM) chips immobilized with antibodies.
These chips show low non-specic adsorption of the serum
components due to the aminosilane surface for easy wash from
the chip.142 The LOD in the AFM chip was compared with two
proteomic technologies such as the electrophoretic/754 | Anal. Methods, 2021, 13, 740–763chromatographic separation of proteins and proteomic micro-
arrays using mass-spectrometric analysis and optical biosensor,
respectively. Thereby, the lower LOD of 101 and 1016 M was
obtained using reversible and irreversible AFM shing, respec-
tively.143 Further, Fourati et al. provided a comprehensive over-
view of the new simplied approaches for screening, diagnosis,
and monitoring HCV infection with different country-specic
settings and described the essential tools in future diagnos-
tics. The POC HCV cAg test kits were difficult to develop and
they were still in the development phase of research.144 Ple-
shakova et al. proposed the HCVcoreAg revelation method,
which has advantages of AFM and target-protein enrichment to
identify the minimum concentration of the detecting antigen in
the AFM chip.145 The sensitivity, DL, and disadvantages of each
HCV antigen detection technique in microuidics are described
in Table 4.This journal is © The Royal Society of Chemistry 2021
Fig. 9 Devices used for the detection of the HCV antigen. (i) Schematic of the MEMS cantilevers with disposable sensor chips; (ii) illustration of
the procedure in the MEMS cantilevers (this figure has been reproduced from ref. 4 with permission from Elsevier, copyright: 2012).


































View Article OnlineHCV antigen and antibody. Initially, Laperche et al. simul-
taneously detected the HCV core Ag and anti-HCV Ab for the
early detection of HCV infection, where the nucleic acid detec-
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This journal is © The Royal Society of Chemistry 2021addition of serum, control, and specic conjugate in suitable
microwells with proper incubation period and washing. The
results were analyzed by absorbance measurement.146 Later,
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View Article Onlinespecicity of a MONOLISA HCV Ag–Ab ULTRA assay to detect
both the antibody and antigen in a microplate coated with
monoclonal antibodies, two recombinant proteins, one
recombinant antigen, and a peptide. Upon the addition of
suitable conjugates 1 and 2 with proper incubation and
washing, the antigen–antibody complex was revealed.147 Simi-
larly, Larrat et al. evaluated the performance of both combined
enzyme immunoassay (cEIA) (MONOLISA HCV Ag–Ab ULTRA
assay) and the POC device (OraQuick® HCV) on FSB and oral
mucosal transudate (OMT) for the detection of the HCV anti-
body. As a result, with FSB specimens, cEIA and the POC device
exhibited 100% specicity and 98.2% and 97.4% sensitivity,
respectively. With OMT specimens, the cEIA sensitivity and
specicity of 71.7% and 94.3%, respectively, and the OraQuick®
HCV sensitivity of 94.6% and specicity of 100% were ob-
tained.148 Moreover, Kania et al. focused on the screening
strategy of DBS sampling and provided the HCV status in
a parallel manner, where the series of blood samples with DBS
were analyzed for the detailed result progress.149 Besides, the
HCV diagnosis at the early stage with advanced method rather
than using standard solutions could provide more keener
results. Applegate et al. also suggested the requirement for the
development of new diagnostic techniques.150 The sensitivity,
DL, and disadvantages of each HCV combined antigen and
antibody detection techniques in microuidics are summarized
in Table 5.
Intricacies faced in HCV diagnosis
The viral evolutionary dynamics and host genetic poly-
morphisms, e.g., the interleukin 28B (IL28B) gene, are vital need
for detecting the outcome of the HCV infection.151,152 Quasis
species have been referred to as the most commonly noted viral
variants in HCV-infected patients, which were pointed out for
the functional diversity of nucleotides between the isolates.153 In
an infected person, the HCV nucleotide sequence is observed to
be varied at the rate of 1% to 5%, branching out to different
subtypes and genotypes as a result of the accumulation of
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756 | Anal. Methods, 2021, 13, 740–763HCV RNA genome sequences. At present, HCV is classied into
eleven genotypes (referred to as 1–11) with a nucleotide
sequence difference of 30–50%, six of which are the main ones
(genotypes 1 to 6).154,155 Within the HCV genotype, several
subtypes (designated as a, b, c, etc.) can be dened, which differ
by 15–30% in their nucleotide sequence.156,157 HCV varies
geographically in the prevalence of genotypes and subtypes.70,158
Genotype 1 is currently the most commonly distributed (46%)
in the world, followed by genotype 3, genotype 2, and genotype
4. Different genotypes have different infections and pathoge-
nicity, affecting the rate of cirrhosis progression and the risk of
HCC. HCV heterogeneity would also lead to different reactions
to antiviral therapies.154,159,160 The development of pan-genotypic
antiviral medicines resulted in the challenge of HCV
heterogeneity.29
The general disadvantage of the conventional technique is
that it requires high levels of skill. Moreover, some of the major
unresolved issues are (i) the perspectives for the universal
screening of HCV, (ii) the need for DAA resistance testing in the
future, and (iii) HCV preventive vaccine.104 The non-invasive
detection of viral infections is always preferred compared to
invasive testing. Biosamples such as saliva, sweat, urine, and
teardrops are extensively used as non-invasive detection
samples. However, in HCV diagnosis, the presence of HCV
antibody concentration in the saliva is much lower than that in
the blood.161,162 Hence, the testing kit should have a high LOD.
During testing, the intricacies of multiple separation and
rinsing steps may put forth the challenges of cross-
contamination, the requirement of expertise persons, and
great time consumption.Passive microfluidic lab-on-chip
devices for viral detections
In general, the need for auxiliary amenities such as a pump or
a pressure controlling system for introducing the uid has been
in demand for the microuidic operational procedure. In some
exceptional cases, they also meet with the prerequisite for somerofluidics
L
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View Article Onlinespecialized electronics or optical equipment that does not fall
into conventional medical or biological laboratory equipment,
resulting in further technical hitches. The area density of the
analyte arrays has been pulled down signicantly due to the
increased space occupied by the auxiliary parts. However,
different substrates are necessary for different applications.
Every substrate has its advantages and disadvantages, and it is
solely based on the application of work. Nevertheless, some of
these substrates are costly.163 The various microuidic chip
design structures have tougher fabrications because of the
multiple layer requirements along with voluminous channels
and valves. These drawbacks have narrowed down the practical
applications of these microuidic amenities in the clinics and
general biological laboratories. On the other hand, multiplexed
POC testing can be achieved through microuidic systems that
will minimize overtreatment, reduce the resistance, and
improve the diagnostic precision and overall quality of care.164
Moreover, the detection of viruses from whole blood requires
plasma separation due to the small size and quantity of viruses.
Microuidic methods draw the basic principles and perform
the extraction efficiently at the micro-scale.165 The simple
hydrodynamic trapping technique has been developed due to
the evolution that could meet with the increased demand in
trapping-based design in microuidic operating procedures. In
this way, the analytes can be well-maintained instead of being
wasted by the existence of an external force. Though the process
is simple, the natural state of the separated particles has been
maintained, which is worthwhile for various research purposes.
The hydrodynamic trapping technique uses a mechanical
barrier to detach the target particle from the central ow. Aer
the separation process, the hydrodynamic trapping sites
maintain hold of the target particles, which paves the way for
future research endeavors. The results from the advancements
of research technologies obtained in the past decades enable
the progress of microuidic systems for rapid diagnostics.166
Critical discussion
During pregnancy and certain emergency trauma situations,
rapid blood transfusion is crucial. Hence, rapid testing of any
infection in the blood is essential. However, some of the most
common sources for the rapid spread of HCV infection are poor
blood transfusion methods with insecure injection practices.
Sometimes, it can be transmitted through personal belongings
such as sharing razors. Thus, a quick diagnosis is obligatory for
reducing disease progression and transmission. The develop-
ment of screening techniques such as EIA, recombinant
immunoblot assay (RIBA), NAT assays, and molecular virolog-
ical methods such as RT-PCR have high specicity and sensi-
tivity in detecting active infection. However, in resource-
constrained clinical settings, these methods are assumed to
be difficult and time-consuming.167–169
People prefer non-invasive modes of diagnosis due to
reduced pain, time-consuming, and discomfort but the sensi-
tivity in oral samples is low compared to blood samples. Anti-
body concentration in the saliva is much lower than that in the
blood, which reduces the accuracy.161 Hence, FDA approval isThis journal is © The Royal Society of Chemistry 2021difficult for diagnostic purposes and it needs further enhance-
ments.170 The further development of advanced primers for
amplicationmay improve the sensitivity of oral samples. POCT
strategies need to be implemented in economically impov-
erished areas.103 Due to these requirements, many POCT have
been developed. The use of the DBS sample provides overall
95% sensitivity and specicity for HCV Ab detection compared
to plasma and serum samples.171 Reverse transcription-
quantitative real-time polymerase chain reaction (RT-qPCR)
has been recommended as the alternative method by the U.S.
Center for Disease Control and Prevention (CDCP).172 Besides
being more specic and sensitive, RT-qPCR methods require
pre-treatment, prior purication of the samples (i.e., urine and
blood), and non-isothermal temperatures for amplication.173
Thus, it forgoes the usage in POCT and resource-limited
settings.
Several techniques are available for antibody detection,
whereas antibodies develop only aer 6–12 weeks of infection.
The FDA approves the OraQuick® Rapid HCV Test for antibody
detection in blood due to its high sensitivity and specicity.
Moreover, false-negative results oen occur for co-infected
patients while using rapid test kits.174 However, in oral uids,
the sensitivity is slightly lower.129 During the initial stage of the
disease, the virus cannot be detected in oral samples but can be
seen in the blood. In addition to this, even aer no active
infection, antibodies can be detected. RNA develops within 2–14
days of infection and increases the ALT. However, detecting ALT
alone is not sufficient as it increases even for minute liver
injury. Thus, RNA and antigen detection modalities are
preferred to diagnose an active infection. The detection time,
window period, and the benets of each biomarker detection
are illustrated in Fig. 10. The high detection time HCV detection
technology enables better accuracy with a decreased window
period. Hence, the requirement of POCT in detecting the RNA
and antigen is vast, whereas only fewer techniques are available
due to the requirement of complex structures and methodolo-
gies in detecting HCV Ag. Furthermore, the detection of Ab and
Ag plays a vital role in determining the infection progression
and treatment plan. From this literature search, the MONOLISA
HCV antibody-antigen ULTRA assay provides high sensitivity
and specicity compared to other techniques but is expensive.
The high sensitivity HCV diagnostic assays for each biomarker
are listed in Table 6.
NAT's RNA detection is the gold standard for diagnosing
active infections but requires expert specialists, expensive
equipment, and dedicated technique.101 Cheap and stable
molecular probes replace costly and unstable antibody aptam-
ers in the AFM chips for target protein enrichment and direct
MS identication but require highly sophisticated laboratory
equipment.145 Many of the assays required a thermocycler or
thermal equipment due to the requirement of different
temperatures in order to bind various components added for
detection. Systems such as Genedrive HCV assay are not fully
automated but battery-operated and suitable for POCT.120 Even
though Genedrive costs less than molecular methods, the
OraQuick® Rapid HCV Test is less expensive than Genedrive.
However, to overcome the high morbidity that occurs inAnal. Methods, 2021, 13, 740–763 | 757
Fig. 10 Characteristic feature of each biomarker detection.
Table 6 HCV diagnostic assays with high sensitivities
Detection Sample type Diagnostic tool Sensitivity Ref.
HCV RNA Serum TAC 100% 116
HCV Ab Oral uid OraQuick® Rapid HCV Test 95.5% 128
Blood OraQuick® HCV Rapid Antibody Test 99.9% 129
HCV Ag Serum and plasma Magnetic microparticle-based assay >97% 140
HCV Ag & Ab DBS MONOLISA HCV antibody–antigen ULTRA assay 100% 149


































View Article Onlinemultiple hepatitis virus infections, the EuDx-HE (A, B, C) POC
test kit was developed to detect anti-HAV IgM, HBsAg, and anti-
HCV but the LOD was not evaluated. Even though several POCT
are available, ltering unwanted things in the blood or plasma
seems problematic. The inexpensive, simple, and low-cost mass
production of paper microuidic enhances blood ltration via
capillary action and viral detection.85,175 The current HCV
detection and quantication methods are not sensitive enough
to detect viral clearance since some individuals show recurrence
by the end of treatment.176 We have listed some of the consid-
erations to be followed while developing any POCT for viral
detection.
 LOC design: the design must be simple, exible, inexpen-
sive, portable, and should provide a long shelf-life period.
Furthermore, cross-contamination and evaporation must be
reduced.
 Integration: the designed LOC should be in such a way that
it is able to be integrated with other thermal sensors, uoro-
scopes, or optical detectors for effortless quantization, scaling,
or scanning of the viral load.
 Genotype identication: genotype identication LOC
devices are obligatory to provide the exact choice of drug for
treatment.758 | Anal. Methods, 2021, 13, 740–763 Sensitivity: the diagnostic tool must have lower LOD such
that the recurrence of infection aer treatment can be reduced.
From these considerations, the ideal design of rapid LOC
will pave the way for portable and easy detection in ambient
temperature via the naked eye or with the help of simple
equipment. Furthermore, the integration of microuidic tech-
nology with the Internet-of-Things and articial intelligence
enhances the digital revolution in telediagnosis and improves
the automatic quantization of the viral load.177 This can be
achieved only with a teamwork of physicists, chemists, clinical
researchers, engineers, materialists, and doctors. Thus,
researchers need to focus on developing a novel microuidic
platform to step into the new era of detection modality.Conclusion and future perspectives
Currently, the costs and complexities of diagnostic algorithms
are essential complications in screening and treatment moni-
toring. With the employment of new treatment procedures, the
current pathway for HCV diagnosis can be simplied for
randomly-accessible assays or reliable HCV cAg assays to
become affordable in high prevalence settings. At present,
plenty of detection techniques are available for HCV antibodies.This journal is © The Royal Society of Chemistry 2021


































View Article OnlineBesides the availability, the detection can be executed only in
the prolonged state of disease. On the other hand, in the case of
HCV antigen detection assays, they could be detected within
a few listed days. However, the facilities available for this
technique are limited. Hence, the researchers must concentrate
on developing novel techniques to detect the disease at an early
stage. Implementing different diagnostic measures followed in
various countries, based on the practice of similar countries
who have already taken the initial steps towards HCV preven-
tion and exploring innovative approaches to reduce the cost of
these tests through large-scale projects in different contexts,
will be the future challenge. Similarly, detection through rapid
assay and POC techniques are not full-edged. Therefore,
researchers can focus on these areas to efficiently detect the
disease before getting at the CHC stage.
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